HUP0200520A2 - 2-szubsztituált 1,2-benzizotiazol-és 3-szubsztituált tetrahidro-piridopirimidinon-származékok alkalmazása agyi ischémia megelőzésére és kezelésére - Google Patents

2-szubsztituált 1,2-benzizotiazol-és 3-szubsztituált tetrahidro-piridopirimidinon-származékok alkalmazása agyi ischémia megelőzésére és kezelésére

Info

Publication number
HUP0200520A2
HUP0200520A2 HU0200520A HUP0200520A HUP0200520A2 HU P0200520 A2 HUP0200520 A2 HU P0200520A2 HU 0200520 A HU0200520 A HU 0200520A HU P0200520 A HUP0200520 A HU P0200520A HU P0200520 A2 HUP0200520 A2 HU P0200520A2
Authority
HU
Hungary
Prior art keywords
substituted
derivatives
prophylaxis
therapy
benzisothiazole
Prior art date
Application number
HU0200520A
Other languages
English (en)
Inventor
Franz Emling
Francisco Javier Garcia-Ladona
Hans-Peter Hofmann
Uta Holzenkamp
Wilfried Lubisch
Kurt Schellhaas
Dorothea Starck
Gerd Steiner
Laszlo Szabo
Liliane Unger
Original Assignee
Basf Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Aktiengesellschaft filed Critical Basf Aktiengesellschaft
Publication of HUP0200520A2 publication Critical patent/HUP0200520A2/hu
Publication of HUP0200520A3 publication Critical patent/HUP0200520A3/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Steroid Compounds (AREA)
HU0200520A 1999-01-11 1999-12-22 Use of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for the prophylaxis and therapy of cerebral ischaemia HUP0200520A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19900544A DE19900544A1 (de) 1999-01-11 1999-01-11 Verwendung von Verbindungen der Formel I zur Prophylaxe und Therapie der zerebralen Ischämie

Publications (2)

Publication Number Publication Date
HUP0200520A2 true HUP0200520A2 (hu) 2002-07-29
HUP0200520A3 HUP0200520A3 (en) 2003-04-28

Family

ID=7893835

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0200520A HUP0200520A3 (en) 1999-01-11 1999-12-22 Use of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for the prophylaxis and therapy of cerebral ischaemia

Country Status (19)

Country Link
EP (1) EP1140099A1 (hu)
JP (1) JP2002534467A (hu)
KR (1) KR20010101440A (hu)
CN (1) CN1333685A (hu)
AR (1) AR029741A1 (hu)
AU (1) AU2285100A (hu)
BG (1) BG105688A (hu)
BR (1) BR9916888A (hu)
CA (1) CA2359390A1 (hu)
DE (1) DE19900544A1 (hu)
HU (1) HUP0200520A3 (hu)
IL (1) IL144145A0 (hu)
MX (1) MXPA01006966A (hu)
NO (1) NO20013408L (hu)
PL (1) PL348916A1 (hu)
SK (1) SK9682001A3 (hu)
TR (1) TR200102009T2 (hu)
WO (1) WO2000041697A1 (hu)
ZA (1) ZA200105473B (hu)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60334016D1 (de) 2002-11-05 2010-10-14 Glaxo Group Ltd Antibakterielle mittel
WO2005030130A2 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Isoquinoline potassium channel inhibitors
AU2006282403B2 (en) * 2005-08-26 2011-07-07 Institute Of Medicinal Molecular Design, Inc. Derivative having PPAR agonistic activity
KR20100063087A (ko) * 2007-09-20 2010-06-10 코텍스 파마슈티칼스, 인크. 글루타메이트 시냅스 반응 향상을 위한 3-치환된 1,2,3-트리아진-4-온 및 3-치환된 1,3-피리미디논
MA41168A (fr) * 2014-12-17 2017-10-24 Acraf Nouveaux composés antibactériens
CN108484594B (zh) * 2018-02-09 2020-08-04 福建医科大学 一种烷氧基取代四氢吡啶并嘧啶类化合物或其可用盐及其制备方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3620643A1 (de) * 1985-06-22 1987-01-22 Sandoz Ag Thiazole, ihre herstellung und verwendung
DE3831888A1 (de) * 1988-09-20 1990-03-29 Troponwerke Gmbh & Co Kg Arzneimittel zur behandlung von apoplexia cerebri
JP3036789B2 (ja) * 1990-06-22 2000-04-24 三井化学株式会社 新規な複素環式化合物及び医薬組成物
DE19746612A1 (de) * 1997-10-22 1999-04-29 Basf Ag 2-Substituierte 1,2-Benzisothiazol-Derivate, ihre Herstellung und Verwendung
DE19747063A1 (de) * 1997-10-24 1999-04-29 Basf Ag 3-substituierte Tetrahydropyridopyrimidinon-Derivate, ihre Herstellung und Verwendung

Also Published As

Publication number Publication date
AR029741A1 (es) 2003-07-16
BG105688A (en) 2002-02-28
IL144145A0 (en) 2002-05-23
CN1333685A (zh) 2002-01-30
HUP0200520A3 (en) 2003-04-28
MXPA01006966A (es) 2002-04-10
NO20013408D0 (no) 2001-07-10
PL348916A1 (en) 2002-06-17
AU2285100A (en) 2000-08-01
EP1140099A1 (de) 2001-10-10
TR200102009T2 (tr) 2002-01-21
BR9916888A (pt) 2001-11-20
WO2000041697A1 (de) 2000-07-20
KR20010101440A (ko) 2001-11-14
SK9682001A3 (en) 2002-03-05
ZA200105473B (en) 2002-10-03
DE19900544A1 (de) 2000-07-13
NO20013408L (no) 2001-08-21
JP2002534467A (ja) 2002-10-15
CA2359390A1 (en) 2000-07-20

Similar Documents

Publication Publication Date Title
IL152754A0 (en) Quinazoline derivatives for the treatment of tumours
ZA200107689B (en) 1-Arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of CNS disorders.
GB0004167D0 (en) 1-piperidinyl-propan-2-ol derivatives and their use as therapeutic agents
HK1053058A1 (zh) 普拉克索用於治療成癮性疾病的用途
HUP0200441A3 (en) Tetrahydropyran derivatives and their use as therapeutic agents and process for preparation the compounds
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
HUP0002742A3 (en) New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
AU2001279709A1 (en) Pyrimidine derivatives and their use for preventing and treating cerebral ischaemia
AU4694999A (en) Use of thiazolidinedione derivatives for the treatment or prevention of cataracts
MXPA03004303A (es) DERIVADOS SUSTITUIDOS DE ACIDO AMINO-FURAN-2-IL-ACETICO Y ACIDO AMINO-TIEN-2-IL-ACETICO Y SU USO PARA EL TRATAMIENTO DE MIGRAnA Y DOLOR.
AU2002220735A1 (en) Substituted derivatives of aminofuran-2-yl-acetic acid and aminothien-2-yl-acetic acid and the use thereof for treating migraines and pain
HUP0203611A3 (en) 14,15-beta-methylene substituted androgens and their use for preparation of the medicaments
AU2002215047A1 (en) Isoquinoline derivatives useful in the treatment of cns disorders
HUP0200520A3 (en) Use of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for the prophylaxis and therapy of cerebral ischaemia
HK1057332A1 (en) Use of 3-benzoylphenylacetic acid derivatives for the treatment of retinal disorders
HK1049122A1 (en) The use of mirtazapine for the treatment of sleep disorders
AU2002215187A1 (en) S-adenosylmethionine and derivatives thereof for the treatment and prevention ofalzheimer's disease
HK1059782A1 (en) Indole derivatives useful for the treatment of cnsdisorders
AU1028501A (en) Isoquinoline and quinazoline derivatives for the treatment of cns disorders
CZ20011872A3 (cs) Isonipekotamidy pro léčbu onemocnění zprostředkovaných integriny
IL131399A0 (en) The use of aryl-cyclohexylamine derivatives against cns disorders
HU9900123D0 (en) 1-isothiazolidinone derivatives of azetidine-2-one, processes for the preparation thereof and use thereof
GB9926985D0 (en) Use of substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and-cyanamides for the treatment of diseases
AU2001287578A1 (en) Substituted thienopyrimidine derivatives and the use thereof for the prophylaxisand therapy of cerebral ischaemia
AU4101900A (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases